share_log

RedHill Biopharma Initiates Phase 2 Study Of RHB-204 In Mycobacterium Avium Subspecies Paratuberculosis-Positive Moderate To Severe CD

Benzinga ·  Mar 12 19:03
RedHill Biopharma Initiates Phase 2 Study Of RHB-204 In Mycobacterium Avium Subspecies Paratuberculosis-Positive Moderate To Severe CD
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment